Affinage

SHROOM3

Protein Shroom3 · UniProt Q8TF72

Length
1996 aa
Mass
216.9 kDa
Annotated
2026-04-28
40 papers in source corpus 24 papers cited in narrative 24 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SHROOM3 is an actin-associated scaffold protein that drives apical constriction and epithelial morphogenesis by recruiting Rho-kinase (ROCK1/2) and actomyosin components to the apical cell surface. Its ASD2 domain directly binds ROCK, and a separation-of-function point mutation (R1838C) that abolishes ROCK binding causes neural tube defects without affecting SHROOM3 localization, establishing ROCK as the principal downstream effector (PMID:18339671, PMID:25171888). Upstream, SHROOM3 apical localization is controlled by RhoA/Trio, p120-catenin, CDC42, and PCP/Dishevelled signaling, while its transcription is activated by Pax6, Pitx factors, and FGF pathways in tissue-specific contexts (PMID:20081189, PMID:20332151, PMID:22031541, PMID:23136387, PMID:25596276). In the kidney, SHROOM3 has domain-separable functions: its ASD2 domain mediates profibrotic TGFβ1/ROCK signaling in tubular cells, whereas a distinct SH3-binding motif recruits FYN kinase to phosphorylate nephrin and maintain the podocyte filtration barrier (PMID:30341149, PMID:41469391).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2008 High

    The identity of the direct downstream effector of Shroom3 during epithelial morphogenesis was established: Shroom3 physically binds ROCK1/2 and recruits them to apical junctions, and disruption of this interaction blocks neural tube closure.

    Evidence Co-immunoprecipitation with reciprocal binding-site mapping (RII-C1 domain), dominant-negative disruption in Xenopus neural tube

    PMID:18339671

    Open questions at the time
    • Crystal structure of the Shroom3–ROCK interface not determined
    • Whether additional effectors contribute independently of ROCK remained open
  2. 2010 High

    Transcriptional control of Shroom3 was linked to tissue-specific morphogenesis: Pax6 activates Shroom3 in the lens placode, and Pitx factors directly drive Shroom3 transcription via cis-regulatory elements, establishing how upstream patterning signals engage the apical constriction machinery.

    Evidence Pax6 mutant mouse lens analysis, Pitx-responsive reporter assays and Shroom3 morpholino epistasis in Xenopus gut

    PMID:20081189 PMID:20332151

    Open questions at the time
    • Whether Pax6 acts directly on Shroom3 regulatory elements or indirectly was not resolved
    • Combinatorial transcriptional regulation in other tissues unexplored
  3. 2011 High

    The upstream signaling hierarchy was clarified: a Trio/RhoA pathway is required for Shroom3 apical localization, and Shroom3 cooperates with N-cadherin downstream of Pitx2 for asymmetric cell shape changes, positioning Shroom3 downstream of both small GTPase and adhesion inputs.

    Evidence Dominant-negative/CA RhoA and Trio knockdown in MDCK cells and mouse lens pit; compound heterozygous mouse genetics for Shroom3/N-cadherin

    PMID:21726547 PMID:22031541

    Open questions at the time
    • Direct physical interaction between RhoA and Shroom3 not shown
    • Whether N-cadherin interaction is direct or via junctional complex was unresolved
  4. 2012 High

    FGF signaling was added as an upstream activator of Shroom3 expression, extending the ROCK-recruitment mechanism to a non-neural context (zebrafish lateral line rosette assembly).

    Evidence Gain/loss-of-function in zebrafish with FGF pathway inhibition and myosin immunofluorescence

    PMID:23136387

    Open questions at the time
    • Whether FGF acts transcriptionally or post-translationally on Shroom3 was not fully dissected
  5. 2014 High

    A separation-of-function mutation (R1838C) proved that ROCK binding through the ASD2 domain is the essential effector mechanism: the mutation abolishes ROCK binding without affecting Shroom3 protein levels or localization, yet phenocopies complete loss of function in neural tube closure.

    Evidence ENU-induced point mutation, in vitro binding assay, in vivo neural tube phenotyping in mouse

    PMID:25171888

    Open questions at the time
    • Whether R1838C also affects other interactions (e.g., 14-3-3) was not tested
  6. 2014 High

    SHROOM3 was linked to chronic kidney disease pathogenesis through two distinct mechanisms: a TCF7L2-dependent enhancer at a CKD-risk locus increases SHROOM3 transcription to drive TGFβ1-mediated tubular fibrosis, and variants in the actin-binding domain impair podocyte/glomerular filtration barrier function.

    Evidence Luciferase enhancer reporter, conditional tubular knockdown in UUO mouse model, congenic rat mapping with zebrafish cross-species rescue

    PMID:25273069 PMID:25437874

    Open questions at the time
    • Whether tubular and glomerular functions of SHROOM3 are mediated by distinct or overlapping downstream pathways was unclear
    • Human genetic causation for Mendelian kidney disease not established
  7. 2015 High

    Shroom3 was placed downstream of planar cell polarity signaling: Shroom3 physically complexes with Dishevelled 2, and Shroom3 pathway components are planar-polarized along mediolateral junctions in a PCP-dependent manner during neural tube closure.

    Evidence Co-immunoprecipitation of Shroom3/Dvl2, double-mutant genetic epistasis (Shroom3/Vangl2, Shroom3/Wnt5a), immunofluorescence of polarized distribution

    PMID:25596276

    Open questions at the time
    • The direct binding interface between Shroom3 and Dishevelled was not mapped
    • How PCP polarizes Shroom3 subcellularly remained unknown
  8. 2016 High

    The glomerular phenotype of Shroom3 loss was characterized at the cellular level: null mice show cystic/collapsing glomeruli with disrupted Rho-kinase/myosin II and loss of apical actin in podocytes, and CDC42 was identified as an upstream regulator of SHROOM3 localization in thyroid bud.

    Evidence Shroom3 null mouse renal histology and EM; conditional Cdc42 KO with Shroom3 gene trap in thyroid

    PMID:26772200 PMID:26940091

    Open questions at the time
    • Whether podocyte defects are ROCK-dependent or involve additional effectors was not dissected
    • CDC42-Shroom3 relationship not tested biochemically
  9. 2018 High

    A ROCK-independent effector arm of SHROOM3 was discovered in podocytes: SHROOM3 binds FYN kinase via an SH3-binding motif distinct from the ROCK-binding ASD2 domain, activates FYN, and drives nephrin phosphorylation to maintain the slit diaphragm; knockdown causes albuminuria and foot process effacement.

    Evidence Endogenous co-immunoprecipitation with domain mapping in human podocytes, inducible shRNA knockdown mouse model, EM

    PMID:30341149

    Open questions at the time
    • Structural basis of the Shroom3-FYN interaction unresolved
    • Whether FYN and ROCK arms cross-talk in podocytes unknown
  10. 2020 High

    The Shroom3/Dvl2/PCP axis was extended to cardiac morphogenesis: loss of Shroom3 disrupts cardiomyocyte polarity and actomyosin organization, causing congenital heart defects.

    Evidence Co-immunoprecipitation of Shroom3/Dvl2, Shroom3 gene trap mice with cardiac phenotyping

    PMID:32511952

    Open questions at the time
    • Whether cardiac defects are ROCK-dependent was not tested
    • Cardiomyocyte-specific conditional deletion not performed
  11. 2021 Medium

    SHROOM3's role was extended beyond development to epithelial repair: Shroom3 is required for actomyosin reorganization and tubular redifferentiation after ischemic acute kidney injury.

    Evidence Shroom3 heterozygous mouse ischemia-reperfusion model, immunofluorescence for actomyosin regulators

    PMID:35368578

    Open questions at the time
    • Single heterozygous model—complete loss-of-function not tested in AKI
    • Downstream signaling pathway in repair context not fully delineated
  12. 2023 Medium

    SHROOM3 function in apical constriction was validated in human and primate neuroepithelial organoid models, confirming conservation of mechanism and demonstrating that these defects are not rescued by folate.

    Evidence CRISPR KO in human brain organoids and cynomolgus monkey neuroepithelial organoids, F-actin/pMLC immunofluorescence, folate rescue experiments

    PMID:37443734 PMID:38287904

    Open questions at the time
    • Folate-independent rescue pathways not identified
    • Whether downstream transcriptomic changes reflect direct ROCK targets not resolved
  13. 2025 High

    Domain-separable functions of SHROOM3 were definitively demonstrated in vivo for kidney disease: ASD2 (ROCK-binding) deletion abrogates profibrotic signaling while preserving FYN-mediated anti-proteinuric function, and small-molecule inhibitors targeting the Shroom3–ROCK interaction reduce fibrosis.

    Evidence Transgenic mice with WT vs. ASD2Δ-Shroom3, multiple renal injury models, phospho-MYPT1 assays, Fyn-binding mutant mice, small molecule P2I inhibitors

    PMID:41469391

    Open questions at the time
    • Clinical translation of Shroom3–ROCK inhibitors not yet tested
    • Whether ASD2 deletion affects non-renal SHROOM3 functions unknown
  14. 2025 Medium

    SHROOM3's morphogenetic role was extended to optic fissure closure, where it is required in RPE for tissue alignment and reestablishment of apical-basal polarity during epithelial fusion.

    Evidence Shroom3 gene trap and conditional floxed KO mice, neural retina-specific Cre ablation, morphological analysis

    PMID:40113025

    Open questions at the time
    • RPE-specific conditional deletion not performed
    • Downstream ROCK involvement in optic fissure closure not directly tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the structural basis of the Shroom3–ROCK and Shroom3–FYN interfaces, how PCP signals regulate Shroom3 subcellular polarization, whether ROCK and FYN pathways cross-regulate in podocytes, and whether Shroom3–ROCK inhibitors can be translated therapeutically for fibrotic kidney disease.
  • No high-resolution structure of any Shroom3 effector complex
  • PCP-dependent polarization mechanism of Shroom3 unknown
  • In vivo therapeutic window for Shroom3-ROCK inhibitors not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 5 GO:0060090 molecular adaptor activity 4
Localization
GO:0005856 cytoskeleton 5 GO:0005886 plasma membrane 3
Pathway
R-HSA-1266738 Developmental Biology 8 R-HSA-162582 Signal Transduction 5 R-HSA-1643685 Disease 5
Partners
DVL2FYNNRP1ROCK1ROCK2VANGL2

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 Shroom3 directly binds ROCK1/2 and recruits them to epithelial apical junctions; a Shroom3-binding site (RII-C1) on ROCKs was identified, and dominant-negative RII-C1 disrupts Shroom3-ROCK interaction, removing apically localized ROCKs and blocking neural tube closure. Co-immunoprecipitation, dominant-negative domain expression, immunofluorescence localization, Xenopus neural tube closure assay Development High 18339671
2010 Shroom3 is required for apical localization of F-actin, myosin II, and Vasp during lens placode invagination, and Shroom3 expression in the lens is transcriptionally activated by Pax6. Loss-of-function mouse genetics, immunofluorescence for F-actin/myosin II/Vasp, genetic epistasis with Pax6 mutants Development High 20081189
2010 Pitx transcription factors directly activate Shroom3 transcription via Pitx-responsive regulatory elements in the Shroom3 genomic locus, and ectopic Pitx expression is sufficient to induce Shroom3-dependent cytoskeletal reorganization and epithelial cell shape change in Xenopus gut. Reporter assays with Pitx-responsive elements, gain-of-function Pitx expression, loss-of-function Shroom3 morpholino knockdown, immunofluorescence Development High 20332151
2011 A Trio (RhoA-GEF)–RhoA–Shroom3 pathway is required for apical constriction during lens pit invagination; RhoA activity is required for Shroom3 apical localization, and apically targeted active RhoA is sufficient to induce apical constriction. Dominant-negative/constitutively active RhoA constructs, Trio knockdown in MDCK cells and mouse lens pit, Rock inhibitor, immunofluorescence Development High 22031541
2011 Shroom3 functions cooperatively with N-cadherin downstream of Pitx2 to regulate asymmetric epithelial cell shape changes in the dorsal mesentery required for gut rotation; genetic interaction shown by compound heterozygotes. Mouse genetics, compound heterozygous analysis, cell morphology measurements Developmental biology Medium 21726547
2012 Shroom3 expression downstream of FGF signaling organizes cell shape changes during rosette assembly in the zebrafish lateral line primordium by recruiting Rho kinase and activating non-muscle myosin. Gain- and loss-of-function experiments in zebrafish, immunofluorescence for myosin, FGF pathway inhibition, rosette quantification Development High 23136387
2014 An ENU-induced R1838C substitution in mouse Shroom3 abolishes ROCK binding without affecting Shroom3 expression or localization, rendering it non-functional for cell morphology regulation and causing neural tube defects, demonstrating ROCK is the major downstream effector of Shroom3 in neural tube morphogenesis. ENU mutagenesis, biochemical binding assays, in vivo neural tube closure phenotyping, sequence conservation analysis Biology open High 25171888
2014 p120-catenin is required for apical constriction of lens cells and functions by recruiting Shroom3 to adherens junctions; genetic interaction and junctional mislocalization of Shroom3 demonstrated in p120-catenin mutants. Mouse genetic interaction (compound heterozygotes), immunofluorescence localization of Shroom3 and p120-catenin, apical constriction quantification Development Medium 25038041
2014 Shroom3 facilitates canonical TGF-β1 signaling and increases COL1A1 expression in renal tubular cells; this is regulated by a TCF7L2-dependent enhancer at the rs17319721 locus that increases SHROOM3 transcription in response to TGF-β1/β-catenin signaling; tubular-specific knockdown of Shroom3 abrogates interstitial fibrosis in UUO mice. Luciferase reporter assay for enhancer function, siRNA knockdown in tubular cells, inducible tubular-specific mouse knockdown, UUO fibrosis model, qRT-PCR, Western blot Journal of Clinical Investigation High 25437874
2014 Variants disrupting the actin-binding domain of SHROOM3 impair podocyte function and the glomerular filtration barrier; wild-type SHROOM3 but not FHH rat SHROOM3 allele rescues glomerular defects in zebrafish shroom3 knockdown. Congenic rat mapping, zebrafish rescue experiments with wild-type vs. mutant alleles, functional complementation Genome research Medium 25273069
2015 Shroom3 functions downstream of planar cell polarity (PCP) signaling during neural tube closure; Shroom3 and Dishevelled 2 co-distribute and form a physical complex; components of the Shroom3 pathway are planar-polarized along mediolateral junctions in a Shroom3- and PCP-dependent manner. Co-immunoprecipitation of Shroom3 and Dishevelled 2, genetic epistasis (Shroom3/Vangl2 and Shroom3/Wnt5a double mutants), immunofluorescence of polarized distribution Biology open High 25596276
2015 A small molecule (CCG-17444) covalently targets Shroom3 Cys1816 to inhibit the Shroom3–Rho kinase protein-protein interaction in vitro and counteracts Nogo66-mediated inhibition of neurite outgrowth, demonstrating that Shroom3-ROCK interaction transduces Nogo66 inhibitory signals. High-throughput screen, in vitro protein-protein interaction assay, covalent mechanism characterization, neurite outgrowth assay with Nogo66 BMC neuroscience Medium 26077244
2016 CDC42 is required upstream of SHROOM3 for apical constriction during thyroid bud morphogenesis; SHROOM3 is expressed in the thyroid bud and its subcellular localization is disrupted in Cdc42-deficient embryos; Shroom3 gene trap mutants fail to exhibit apical constriction in the thyroid bud epithelium. Conditional Cdc42 knockout, Shroom3 gene trap mutants, immunofluorescence localization, morphological analysis of thyroid bud Biology open Medium 26772200
2016 Shroom3 null mice exhibit glomerular abnormalities including cystic and collapsing glomeruli and disrupted podocyte arrangement; these defects are associated with altered Rho-kinase/myosin II signaling and loss of apically distributed actin in podocytes. Shroom3 null mouse analysis, immunofluorescence for myosin II and F-actin, renal histology, electron microscopy Journal of the American Society of Nephrology High 26940091
2018 SHROOM3 interacts with FYN (a Src kinase) via a critical SH3-binding domain distinct from its ROCK-binding domain; Shroom3-Fyn interaction is required for activation of Fyn kinase and downstream nephrin phosphorylation in podocytes; Shroom3 knockdown induces albuminuria with podocyte foot process effacement. Co-immunoprecipitation of endogenous SHROOM3 with FYN in human podocytes, domain mapping, inducible shRNA knockdown mouse model, electron microscopy, glomerular RNA-sequencing Journal of the American Society of Nephrology High 30341149
2018 A CKD-associated SHROOM3 variant (P1244L) attenuates the interaction of SHROOM3 with 14-3-3 proteins, suggesting alterations to Hippo pathway signaling; additionally, the rs17319721 variant disrupts TCF7L2 binding to the SHROOM3 locus in podocyte nuclear extracts. Biophysical interaction assays, CRISPR/Cas9 editing, nuclear extract binding assays, cell transcription assays Journal of the American Society of Nephrology Medium 29476007
2020 SHROOM3 interacts physically and genetically with Dishevelled 2 during cardiac development and is downstream of PCP signaling; loss of Shroom3 disrupts actomyosin cytoskeleton, cardiomyocyte polarity, and organization, causing congenital heart defects including ventricular septal defects and double outlet right ventricle. Co-immunoprecipitation of Shroom3 and Dishevelled 2, Shroom3 gene trap knockout mice, cardiac immunofluorescence for actomyosin components, genetic epistasis Developmental biology High 32511952
2021 Shroom3 is required for epithelial repair and redifferentiation after ischemic AKI through organization of actomyosin regulators; Shroom3 heterozygous mice show disrupted Rho-kinase/myosin signaling and disorganized apical F-actin after tubular injury. Shroom3 heterozygous mouse ischemia-reperfusion model, immunofluorescence for actomyosin regulators, MDCK cell actin organization assay Kidney360 Medium 35368578
2023 SHROOM3 knockout in brain organoids causes expansion of the apical lumen and reduced F-actin polarization, demonstrating that Shroom3 is required for apical constriction of neuroepithelial cells, sharing a pathogenic mechanism with valproic acid-induced NTDs. CRISPR/Cas9 knockout in human brain organoids, high-throughput image analysis, F-actin immunofluorescence, RNA sequencing Cells Medium 37443734
2024 NRP1 interacts with Shroom3 via protein-protein interaction (confirmed by co-immunoprecipitation and protein docking); GAG-modified NRP1 recruits Shroom3, and non-GAG-modified NRP1 (S612A mutant) fails to recruit Shroom3 and cannot promote osteo/odontogenic differentiation in dental pulp stem cells. Co-immunoprecipitation, confocal colocalization, protein-protein docking, NRP1 S612A loss-of-function, Shroom3 knockdown Biochimica et Biophysica Acta - Molecular Cell Research Medium 39033931
2024 Loss of SHROOM3 in cynomolgus monkey neuroepithelial organoids results in shorter neuroepithelial cells due to insufficient apical recruitment of F-actin, myosin II, and phospho-myosin light chain; these defects are not rescued by folate supplementation. SHROOM3 knockout in primate neuroepithelial organoids, immunofluorescence for cytoskeletal proteins, folate rescue experiments, RNA sequencing Zoological research Medium 38287904
2025 The Shroom3 ASD2 domain (ROCK-binding domain) mediates profibrotic signaling in renal tubular cells and fibroblasts; ASD2-deletion mutant Shroom3 fails to activate ROCK (phospho-MYPT1), and transgenic mice overexpressing ASD2Δ-Sh3 show reduced TIF compared to WT-Sh3 mice; a distinct Fyn-binding motif in Shroom3 mediates its anti-proteinuric function. Transgenic mice overexpressing WT vs. ASD2Δ-Sh3, HEK293T/mIMCD cell lines, UUO and aristolochic nephropathy models, phospho-MYPT1 assay, Fyn-binding mutant mice, small molecule P2I inhibitors Nature communications High 41469391
2025 VANGL2 and SHROOM3 cooperate in the splanchnic mesoderm to control bilateral symmetry during heart tube morphogenesis; apically localized VANGL2 acts through its downstream actin-binding effector SHROOM3. 3D quantification of heart geometry in VANGL2 mutants, chick cell labeling, immunolocalization of VANGL2 and SHROOM3 bioRxiv (preprint)preprint Low bio_10.1101_2025.09.05.674213
2025 Shroom3 is required for optic fissure closure; it is apically localized in neural retina and RPE and its deficiency increases apical cell surface area, disrupts tissue alignment, and impairs reestablishment of apical-basal polarity during epithelial fusion. Neural retina-specific ablation shows RPE Shroom3 function is likely sufficient for tissue alignment. Shroom3 gene trap and floxed conditional knockout mice, immunofluorescence, neural retina-specific Cre ablation, morphological analysis Developmental biology Medium 40113025

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development (Cambridge, England) 245 18339671
2010 Pax6-dependent Shroom3 expression regulates apical constriction during lens placode invagination. Development (Cambridge, England) 103 20081189
2011 A Trio-RhoA-Shroom3 pathway is required for apical constriction and epithelial invagination. Development (Cambridge, England) 99 22031541
2014 Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. The Journal of clinical investigation 71 25437874
2015 Shroom3 functions downstream of planar cell polarity to regulate myosin II distribution and cellular organization during neural tube closure. Biology open 70 25596276
2014 Shroom3 contributes to the maintenance of the glomerular filtration barrier integrity. Genome research 66 25273069
2012 Shroom3 is required downstream of FGF signalling to mediate proneuromast assembly in zebrafish. Development (Cambridge, England) 54 23136387
2011 SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing. Genome biology 54 21936905
2016 Developmental Origins for Kidney Disease Due to Shroom3 Deficiency. Journal of the American Society of Nephrology : JASN 52 26940091
2014 p120-catenin-dependent junctional recruitment of Shroom3 is required for apical constriction during lens pit morphogenesis. Development (Cambridge, England) 51 25038041
2011 Shroom3 and a Pitx2-N-cadherin pathway function cooperatively to generate asymmetric cell shape changes during gut morphogenesis. Developmental biology 49 21726547
2018 Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD. Journal of the American Society of Nephrology : JASN 47 29476007
2010 Direct activation of Shroom3 transcription by Pitx proteins drives epithelial morphogenesis in the developing gut. Development (Cambridge, England) 47 20332151
2014 The interaction between Shroom3 and Rho-kinase is required for neural tube morphogenesis in mice. Biology open 36 25171888
2020 SHROOM3 is downstream of the planar cell polarity pathway and loss-of-function results in congenital heart defects. Developmental biology 25 32511952
2018 SHROOM3-FYN Interaction Regulates Nephrin Phosphorylation and Affects Albuminuria in Allografts. Journal of the American Society of Nephrology : JASN 22 30341149
2020 SHROOM3, the gene associated with chronic kidney disease, affects the podocyte structure. Scientific reports 18 33273487
2023 A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects. Cells 17 37443734
2022 Global analysis of cell behavior and protein dynamics reveals region-specific roles for Shroom3 and N-cadherin during neural tube closure. eLife 17 35244026
2022 Cardiac Cx43 Signaling Is Enhanced and TGF-β1/SMAD2/3 Suppressed in Response to Cold Acclimation and Modulated by Thyroid Status in Hairless SHRM. Biomedicines 13 35885012
2016 Thyroid bud morphogenesis requires CDC42- and SHROOM3-dependent apical constriction. Biology open 11 26772200
2015 Targeted inhibition of the Shroom3-Rho kinase protein-protein interaction circumvents Nogo66 to promote axon outgrowth. BMC neuroscience 11 26077244
2021 Shroom3, a Gene Associated with CKD, Modulates Epithelial Recovery after AKI. Kidney360 10 35368578
2017 The influence of living donor SHROOM3 and ABCB1 genetic variants on renal function after kidney transplantation. Pharmacogenetics and genomics 10 27779570
2023 The Good and the Bad of SHROOM3 in Kidney Development and Disease: A Narrative Review. Canadian journal of kidney health and disease 8 38107159
2023 Minimal Kidney Disease Phenotype in Shroom3 Heterozygous Null Mice. Canadian journal of kidney health and disease 7 37313360
2022 In vivo high-content imaging and regression analysis reveal non-cell autonomous functions of Shroom3 during neural tube closure. Developmental biology 6 36113571
2024 Loss of SHROOM3 affects neuroepithelial cell shape through regulating cytoskeleton proteins in cynomolgus monkey organoids. Zoological research 4 38287904
2025 Shroom3 facilitates optic fissure closure via tissue alignment and reestablishment of apical-basal polarity during epithelial fusion. Developmental biology 3 40113025
2025 Clinical and Metabolic Signatures of FAM47E-SHROOM3 Haplotypes in a General Population Sample. Kidney international reports 3 40485680
2025 Understanding the role of Shroom3 in the developing mouse myocardium. PloS one 2 40920782
2024 Shroom3-Rock interaction and profibrotic function: Resolving mechanism of an intronic CKD risk allele. bioRxiv : the preprint server for biology 2 39605692
2025 Pathogenic variants in SHROOM3 associated with hemifacial microsomia. Journal of human genetics 1 39875538
2025 Common cis-regulatory variation modifies the penetrance of pathogenic SHROOM3 variants in craniofacial microsomia. Genome research 1 40234029
2024 NRP1 promotes osteo/odontogenic differentiation via shroom3 in dental pulp stem cells. Biochimica et biophysica acta. Molecular cell research 1 39033931
2025 SHROOM3 Deficiency Aggravates Adriamycin-Induced Nephropathy Accompanied by Focal Adhesion Disassembly and Stress Fiber Disorganization. Cells 0 40558522
2025 Mapping Shroom3 expression across the adult mouse. Gene expression patterns : GEP 0 41101717
2025 Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction. Nature communications 0 41469391
2025 A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease. Molecular genetics and metabolism 0 41483748
2023 A Shared Pathogenic Mechanism for Valproic Acid and SHROOM3 Knockout in a Brain Organoid Model of Neural Tube Defects. bioRxiv : the preprint server for biology 0 37090564